MTM Investment Management LLC Cuts Stock Position in Pfizer Inc. (NYSE:PFE)

MTM Investment Management LLC lessened its position in Pfizer Inc. (NYSE:PFE) by 23.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,280 shares of the biopharmaceutical company’s stock after selling 4,354 shares during the quarter. MTM Investment Management LLC’s holdings in Pfizer were worth $379,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of PFE. Raab & Moskowitz Asset Management LLC increased its holdings in Pfizer by 10.2% during the 4th quarter. Raab & Moskowitz Asset Management LLC now owns 285,567 shares of the biopharmaceutical company’s stock worth $7,576,000 after purchasing an additional 26,433 shares during the period. Van ECK Associates Corp increased its holdings in Pfizer by 28.5% during the 4th quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock worth $564,739,000 after purchasing an additional 4,726,549 shares during the period. Harvey Capital Management Inc. purchased a new stake in Pfizer during the 4th quarter worth about $544,000. Kentucky Trust Co purchased a new stake in Pfizer during the 4th quarter worth about $1,666,000. Finally, Gladstone Institutional Advisory LLC increased its holdings in Pfizer by 9.0% during the 4th quarter. Gladstone Institutional Advisory LLC now owns 164,432 shares of the biopharmaceutical company’s stock worth $4,362,000 after purchasing an additional 13,587 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.3 %

Pfizer stock opened at $25.46 on Thursday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a 50 day moving average of $26.28 and a two-hundred day moving average of $27.65. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $144.28 billion, a price-to-earnings ratio of 18.06, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period last year, the firm earned $0.10 EPS. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.76%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on PFE shares. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Truist Financial dropped their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Sanford C. Bernstein initiated coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. Finally, Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.